Edition:
United Kingdom

Pfizer Ltd (PFIZ.NS)

PFIZ.NS on National Stock Exchange of India

3,265.55INR
16 Jul 2019
Change (% chg)

-- (--)
Prev Close
Rs3,265.55
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
13,617
52-wk High
Rs3,847.70
52-wk Low
Rs2,501.00

Latest Key Developments (Source: Significant Developments)

EMA Says CHMP Recommends Granting A Conditional Marketing Authorisation For Waylivra
Friday, 1 Mar 2019 

March 1 (Reuters) - EMA - :EMA - CHMP RECOMMENDED GRANTING A CONDITIONAL MARKETING AUTHORISATION FOR ONDEXXYA.EMA - CHMP RECOMMENDED GRANTING A CONDITIONAL MARKETING AUTHORISATION FOR WAYLIVRA.EMA - ZYNQUISTA INTENDED AS AN ADJUNCT TO INSULIN FOR CERTAIN PATIENTS WITH TYPE 1 DIABETES, RECEIVED A POSITIVE OPINION FROM CHMP.EMA - CHMP ADOPTED A POSITIVE OPINION, RECOMMENDING GRANTING OF A CONDITIONAL MARKETING AUTHORISATION FOR LORVIQUA.EMA - CHMP RECOMMENDED FOR APPROVAL GENERIC MEDICINE PAZENIR FOR TREATMENT OF METASTATIC BREAST CANCER AND NON-SMALL CELL LUNG CANCER.EMA - APPLICANT FOR DOXOLIPAD HAS REQUESTED A RE-EXAMINATION OF COMMITTEE'S NEGATIVE OPINION FOR THIS MEDICINE ADOPTED AT JANUARY 2019 MEETING.EMA - CHMP RECOMMENDED EXTENSION OF INDICATION OF DUPIXENT AS ADD-ON MAINTENANCE TREATMENT FOR PATIENTS 12 YRS & OLDER WITH FORMS OF SEVERE ASTHMA.EMA - CHMP WILL NOW RE-EXAMINE OPINION FOR DOXOLIPAD AND ISSUE A FINAL RECOMMENDATION.EMA - APPLICATION FOR AN INITIAL MARKETING AUTHORISATION FOR EPJEVY (PACRITINIB CITRATE) WAS WITHDRAWN.EMA - OTHER EXTENSIONS OF INDICATION RECOMMENDED BY COMMITTEE WERE FOR LYNPARZA, RIARIFY, TRYDONIS AND VIREAD.  Full Article

India's Pfizer Dec-Qtr Profit Rises
Thursday, 24 Jan 2019 

Jan 24 (Reuters) - Pfizer Ltd ::DEC QUARTER NET PROFIT 1.32 BILLION RUPEES VERSUS 872.4 MILLION RUPEES YEAR AGO.DEC QUARTER REVENUE FROM OPERATIONS 5.14 BILLION RUPEES VERSUS 4.57 BILLION RUPEES YEAR AGO.  Full Article

Pfizer Ltd Says Pfizer Inc Has Not Yet Made Decision w.r.t Strategic Alternatives For Global Consumer Healthcare Business​
Thursday, 1 Mar 2018 

March 1 (Reuters) - Pfizer Ltd ::‍PFIZER INC. TOLD CO'S BOARD THAT NO DECISION HAS YET BEEN MADE WITH RESPECT TO ANY STRATEGIC ALTERNATIVES FOR GLOBAL CONSUMER HEALTHCARE BUSINESS​.PFIZER INC IDENTIFIED PRODUCTS OUTSIDE CONSUMER HEALTHCARE BUSINESS IN INDIA TO BE INCLUDED STRATEGIC ALTERNATIVES REVIEW FOR BUSINESS.  Full Article

Pfizer Says Ravi Prakash Bhagavathula Resigned As CFO
Monday, 19 Feb 2018 

Feb 19 (Reuters) - Pfizer Ltd ::SAYS RAVI PRAKASH BHAGAVATHULA RESIGNED AS CFO.  Full Article

FDA Approves SGLT2 Inhibitor Steglatro And Fixed-Dose Combination Steglujan For Adults With Type 2 Diabetes
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Merck & Co Inc ::FDA APPROVES SGLT2 INHIBITOR STEGLATRO™ (ERTUGLIFLOZIN) AND FIXED-DOSE COMBINATION STEGLUJAN™ (ERTUGLIFLOZIN AND SITAGLIPTIN) FOR ADULTS WITH TYPE 2 DIABETES.MERCK & CO INC - FDA APPROVED STEGLATRO TABLETS, AN ORAL SODIUM-GLUCOSE COTRANSPORTER 2 INHIBITOR, AND FIXED-DOSE COMBINATION STEGLUJAN TABLETS.MERCK & CO INC - IN ADDITION TO STEGLATRO & STEGLUJAN, FDA ALSO APPROVED FIXED-DOSE COMBINATION SEGLUROMET.  Full Article

Pfizer Sept-qtr profit down about 12 pct
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Pfizer Ltd ::Sept quarter net profit 1.11 billion rupees versus profit of 1.26 billion rupees last year.Sept quarter revenue from operations 5.71 billion rupees versus 5.58 billion rupees last year.  Full Article